EBV-associated NK and T-cell lymphoid neoplasms.

Details

Serval ID
serval:BIB_6B78B29089F5
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
EBV-associated NK and T-cell lymphoid neoplasms.
Journal
Current opinion in oncology
Author(s)
Kimura H., de Leval L., Cai Q., Kim W.S.
ISSN
1531-703X (Electronic)
ISSN-L
1040-8746
Publication state
Published
Issued date
01/09/2022
Peer-reviewed
Oui
Volume
34
Number
5
Pages
422-431
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Epstein-Barr virus (EBV)-associated neoplasms derived from natural killer (NK) or T cells comprise a group of clinically and biologically heterogenous disorders affecting children and adults, which are overall rare but more prevalent in Asia and South America. This review focuses on neoplasms presenting in the adulthood, addressing recent genomic discoveries as well as therapeutic developments in these highly aggressive disorders.
Distinct molecular subtypes of extranodal NK/T-cell lymphomas (ENKTCLs) have been described, with differences in cell of origin, EBV pattern, genomic alterations, clinical characteristics, response to asparaginase-based therapies and to more recent approaches targeting molecular aberrations of the lymphoma. For the last two decades, progress in the clinical management of ENKTCL was based on L-asapraginase containing combinations and the incoroperation of radiotherapy. A subset of cases with PDL1-2 structural alterations may be more responsive to treatment with immune checkpoint inhibitors. Primary nodal EBV+ lymphomas derived from T or NK cells have distinctive features separating them from both peripheral T-cell lymphoma not otherwise specified and ENKTCL. Treatment algorithms correspond to those for advanced ENKTCL.
With better understanding of lymphomagenesis, genomic landscape and immunologic aspects of the diseases, future treatment options will include targeted therapies including immune checkpoint inhibitors and novel antibodies.
Keywords
Adult, Child, Epstein-Barr Virus Infections/complications, Epstein-Barr Virus Infections/pathology, Herpesvirus 4, Human/genetics, Humans, Immune Checkpoint Inhibitors, Lymphoma, Extranodal NK-T-Cell/therapy, T-Lymphocytes
Pubmed
Web of science
Create date
08/08/2022 7:01
Last modification date
27/08/2022 5:40
Usage data